On 11 November 2025, Tianjin Development Holdings Limited (Stock Code: 882) released details of a transaction involving its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (“Lisheng Pharmaceutical”). Lisheng Pharmaceutical entered into an agreement with China Bohai Bank Co., Ltd. to subscribe for a structured deposit with a principal amount of RMB210,000,000, equivalent to approximately HK$229,759,300.
The subscription is scheduled to run from 13 November 2025 to 13 November 2026, offering a principal-guaranteed return. The expected annualised rate of return ranges from 1.20% to 2.00%, split into a fixed portion of 1.20% and a floating portion determined by the central parity rate of EUR/USD displayed on Bloomberg’s “BFIX (Bloomberg FX Fixings)” page. Lisheng Pharmaceutical’s management explained that the structured deposit is intended to optimise the use of idle funds under the group’s risk management and treasury policies.
As this subscription exceeds 5% but remains under 25% of the applicable percentage ratios, it qualifies as a discloseable transaction under Chapter 14 of the Listing Rules and is therefore subject to reporting and announcement requirements. According to the announcement, the transaction will not affect working capital or business operations, and the company’s board believes it supports overall financial objectives and is in the best interests of shareholders.
Tianjin Development Holdings Limited is principally engaged in investment holding, while its broader group activities cover utilities, pharmaceuticals, hotel operations, electrical and mechanical products, as well as various strategic and other investments.
Comments